Summary & Overview
HCPCS J2021: Linezolid Injection, 200 mg
HCPCS Level II code J2021 denotes a 200 mg injection of linezolid (Hospira), a specific injectable antibiotic formulation that is not therapeutically equivalent to J2020. This code matters nationally because it distinguishes a proprietary product for pharmacy and medical billing, affecting how facilities and payers process claims for inpatient-outpatient drug administration and infusion services. Accurate use of J2021 ensures correct product identification for coding, reimbursement, and pharmacy inventory management.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical and billing context for J2021, typical sites of service where the code is billed (hospital outpatient departments, clinics, and infusion centers), and the implications of product-specific coding for claims processing. The publication summarizes benchmark considerations, potential policy or coverage nuances tied to product-specific HCPCS coding, and practical points for coding workflows.
This resource is intended for coding professionals, revenue cycle leaders, pharmacy billing staff, and policy analysts seeking a national-level reference for proper identification and administrative handling of injectable linezolid billed with J2021. Data not available in the input for payer-specific coverage rules, modifiers usage by payer, and associated ICD-10 diagnoses.
Billing Code Overview
HCPCS Level II code J2021 represents an injection of linezolid (Hospira), specified as 200 mg, noted as not therapeutically equivalent to J2020. This code describes the drug product administered by injection and is used for billing the specific linezolid formulation identified in the descriptor.
Service Type: Drug administration (injectable antibiotic)
Typical Site of Service: Hospital outpatient department, clinic, or infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 68-year-old hospitalized patient with a documented methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection and clinical intolerance to vancomycin due to acute kidney injury is prescribed intravenous linezolid. The medication is billed as J2021 for 200 mg of linezolid (Hospira), a non-therapeutically equivalent product to J2020. The clinical workflow includes physician order entry in the inpatient electronic medical record, pharmacy verification of dose and product selection, preparation of the IV injection by pharmacy or authorized technician under sterile conditions, administration by a registered nurse, and documentation of lot number and discarded product if partially used. Billing staff append the appropriate HCPCS code J2021 to the claim, apply clinically relevant modifiers as needed (for example, JW for discarded medication), and ensure diagnosis linkage to the infectious disease ICD-10 code supporting medical necessity. Typical sites of service include acute inpatient hospital units, observation units, and skilled nursing facilities when IV therapy is continued. Common patient monitoring includes serial laboratory tests (renal function, CBC with differential), clinical assessment of infection source control, and monitoring for thrombocytopenia or neuropathy during prolonged therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|